Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 16/20 | 0.67 |
| ▸ | INSR | P06213 | 2/20 | 0.66 |
| ▸ | IGF1R | P08069 | 2/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24625474 | 0.93 | ALK (0.78) | PLK1ALKINSRIGF1REGFR | |
| SCHEMBL24625380 | 0.91 | ALK (0.65) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL29771865 | 0.91 | ALK (0.65) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL24625600 | 0.91 | PLK1 (0.57) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL30757876 | 0.91 | PLK1 (0.57) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL24625371 | 0.89 | SLC2A1 (0.56) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL27057069 | 0.87 | ALK (0.65) | PLK1ALKIGF1R | |
| SCHEMBL30757875 | 0.86 | PLK1 (0.54) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL24625370 | 0.86 | PLK1 (0.54) | PLK1ALKINSRIGF1RMAP3K7 | |
| SCHEMBL30757880 | 0.85 | ALK (0.67) | PLK1ALKINSRIGF1RMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-01-25 | — | — | US | disclosed |
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025887-A1 | THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, PNKP | PLK1 176/4885ALK 287/4885INSR 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.